Breaking: Pfizer's activist says board must 'hold management accountable' for R&D shortcomings

Max Bayer

Pharma Reporter

Activist investor Starboard Value said Pfizer’s executives haven’t delivered on what they once called one of the best pipelines in the industry, and need to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Breaking: Pfizer's activist says board must 'hold management accountable' for R&D shortcomings

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Roche, Genentech end anti-tau Alzheimer’s drug collaboration with UCB

AvenCell gets $112M to build switchable CAR-T therapies for ‘the last frontier’ of blood cancers

FDA hits Camurus with CRL for acromegaly therapy over manufacturing issues

Q3 biotech roundup: The 2024 turnaround sputters into a critical Q4 finale

Starboard takes activist stake in J&J consumer spinout Kenvue

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Break­ing: Pfiz­er's ac­tivist says board must 'hold man­age­ment ac­count­able' for R&D short­com­ings

Pharma Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Breaking: Pfizer's activist says board must 'hold management accountable' for R&D shortcomings